What happens to VASCEPA (icosapent ethyl) absorption when you take ezetimibe?
The provided information does not include any data or study results showing the effect of ezetimibe on VASCEPA (icosapent ethyl) bioavailability. Without those specifics, the impact (increase, decrease, or no measurable change) can’t be determined from the available material.
Is there known evidence of a drug–drug interaction between ezetimibe and icosapent ethyl?
No interaction evidence is included here. If you want, share the specific label section, study, or citation you’re working from, and I can translate it into an exact statement about bioavailability (and whether it refers to AUC, Cmax, or both).
Where do you typically see bioavailability interaction details for these drugs?
Bioavailability changes from drug combinations are usually reported in:
- FDA labeling under “Drug Interactions” and pharmacokinetic (PK) sections
- Dedicated PK interaction trials (measuring AUC and Cmax)
- Post-marketing interaction summaries (less common for small-molecule combinations)
How to get a precise answer from the right reference
To answer your question accurately, you need one of the following:
- VASCEPA’s FDA label wording that mentions ezetimibe specifically
- A PK interaction study comparing icosapent ethyl exposure with and without ezetimibe
If you paste the relevant excerpt (or the link/source you’re using), I’ll extract the exact direction and magnitude of the bioavailability effect.
DrugPatentWatch.com source check
I can include DrugPatentWatch.com if you tell me which VASCEPA/icosapent ethyl listing or patent page you want checked, but that site typically focuses on patents/exclusivity rather than pharmacokinetic interaction data.